Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Nymox Pharmaceutical Corporation : Nymox Announces Positive Safety Monitoring Committee Results for Phase 3 NX-1207 Trials for BPH
4-Traders
Saturday, April 28, 2012 - 12:57pm
tags:
Nymox, NX-1207, benign prostatic hyperplasia, BPH
Sanofi first quarter profit climbs 13% on Genzyme, Lantus
The Star Ledger, NJ
Saturday, April 28, 2012 - 12:55pm
tags:
Sanofi, earnings
Novo Nordisk Finally Looks (Slightly) Mortal
Seeking Alpha
Saturday, April 28, 2012 - 12:54pm
tags:
Novo Nordisk
Plant-Made Pharmaceuticals And The Democratization Of Health Care
Seeking Alpha
Saturday, April 28, 2012 - 12:52pm
tags:
iBio
Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Pharmalive
Saturday, April 28, 2012 - 12:50pm
tags:
ONYX Pharmaceuticals, Carfilzomib, Multiple Myeloma
Threshold Pharmaceuticals: TH-302 Phase IIb Clinical Results In First-Line Pancreatic Cancer
Seeking Alpha
Saturday, April 28, 2012 - 12:43pm
tags:
TH-302, pancreatic cancer, Threshold Pharmaceuticals
Merck's Q1 Results Mixed; All Eyes On Drug Pipeline
Yahoo/Investors
Saturday, April 28, 2012 - 12:34pm
tags:
Merck, earnings
Merck Wins U.S. ZETIA® (ezetimibe)/ VYTORIN® (ezetimibe/simvastatin) Patent Infringement Lawsuit
Yahoo/BusinessWire
Saturday, April 28, 2012 - 12:29pm
tags:
Merck, Zetia, lawsuits, patents, Mylan, generics
Sanofi-Aventis's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Seeking Alpha
Saturday, April 28, 2012 - 12:28pm
tags:
Sanofi, earnings
A Strong Pick For Long-Term Investors
Motley Fool
Saturday, April 28, 2012 - 12:26pm
tags:
JNJ
Come On, Amylin, Just a Little Clue?
Motley Fool
Saturday, April 28, 2012 - 12:26pm
tags:
Amylin, Bristol-Myers Squibb, M&A
GlaxoSmithKline PLC (GSK): Today's Featured Health Care Winner
The Street
Saturday, April 28, 2012 - 12:24pm
tags:
GSK
Maybe There Will Be Some Hep C Patients Left
Motley Fool
Saturday, April 28, 2012 - 12:21pm
tags:
hepatitis C
Disappointed By Celgene's Q1? Take The Long View
Seeking Alpha
Saturday, April 28, 2012 - 12:20pm
tags:
Celgene, earnings
Anemic Growth? Not From These Drugs.
Motley Fool
Saturday, April 28, 2012 - 12:19pm
tags:
Amgen, Affymax, Takeda, Epogen, Aranesp, Pfizer, Abbott Laboratories, JNJ, Novartis, Zometa, Xgeva, Prolia
Investors Actively Trade These 4 Healthcare Stocks Post Earnings
Wall St. Cheat Sheet
Saturday, April 28, 2012 - 12:15pm
tags:
Gilead Sciences, Vertex Pharmaceuticals, Athenahealth, Cerner
Why InterMune Shares Got Crushed
Motley Fool
Saturday, April 28, 2012 - 11:41am
tags:
InterMune, earnings
A Little Confidence Goes a Long Way
Motley Fool
Saturday, April 28, 2012 - 11:40am
tags:
Keryx, Aeterna Zentaris, Zerenex, renal disease, kidney disease, Torii Pharmaceutical
Vivus Announces FDA Approval Of STENDRA™ (avanafil) Tablets For The Treatment Of Erectile Dysfunction
Yahoo/PR NewsWire
Saturday, April 28, 2012 - 11:37am
tags:
Vivus, Stendra, Avanafil, erectile dysfunction
Seeing Black Gives Regeneron a 9% Pop
Motley Fool
Saturday, April 28, 2012 - 11:35am
tags:
Regeneron, Eylea, macular degeneration

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.